Foundation - What Retatrutide Already Provides Retatrutide is the most potent single-agent weight-loss peptide in late-stage trials
With zero sugar, zero fat, and only 3 kcal per can, this vegan-friendly drink offers a low-calorie solution for anyone aiming to improve alertness and concentration without compromising dietary goals
Barnes et al
More recently, a breakthrough 2026 study utilizing both in-vitro cellular models and an in-vivo human pharmacokinetic trial further solidified these findings
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
What does PlexusDx offer related to skin health and personalization
